Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00898079

Enrollment

2545

Registered

2009-05-12

Start date

2003-10-13

Completion date

2018-06-30

Last updated

2018-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia

Brief summary

This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.

Detailed description

OBJECTIVES: I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol. II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients. III. Make specimens available to qualified researchers to understand the biology of cancer in these patients. OUTLINE: Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.

Interventions

OTHERCytology Specimen Collection Procedure

Correlative studies

Eligibility

Sex/Gender

ALL

Age

No minimum to 30 Years

Healthy volunteers

Inclusion criteria

* Meets any of the following criteria: * Diagnosed with primary neoplasm * Developed a second malignant neoplasm * Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition * Must have biological specimens including solid tumors and leukemias available * Solid tumors meeting the following criteria: * Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed) * Slides for pathology review (instead of slides for QC) are required for patients with rare tumors * Pleural fluid or cytologic specimens meeting the following criteria: * At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears) * Slides for pathology review (instead of slides for QC) are required for patients with rare tumors * ALL/AML * 3-6 mL of bone marrow aspirate and 10 mL of whole blood * Not eligible for disease-specific biology or banking protocol

Design outcomes

Primary

Measure	Time frame
Repository of malignant, borderline malignant neoplasms, and related biological specimens	Baseline

Countries

Australia, Canada, New Zealand, Puerto Rico, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026